Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q2
Sell
-200
Closed -$3K 814
2022
Q1
$3K Buy
+200
New +$13.7K ﹤0.01% 872

Other funds holding ACLS

Moors & Cabot's ACLS Position: Q2 2026 in Review

Moors & Cabot increased its Axcelis (ACLS) stake by 7.1% in Q2 2026, buying an estimated $44.5K and bringing the position to 4,500 shares worth $853K. The position accounts for 0.03% of the portfolio, ranked #432.

Moors & Cabot first reported a position in ACLS in Q1 2021 and has held it in 22 quarters since. The position peaked at $1.88M in Q2 2023. 441 funds tracked by Wall St. Rank hold ACLS as of Q2 2026.

  • Moors & Cabot held 4,500 shares of Axcelis worth $853K as of Q2 2026.
  • Moors & Cabot bought 300 Axcelis shares in Q2 2026, an estimated $44.5K.
  • Axcelis made up 0.03% of Moors & Cabot's portfolio in Q2 2026, its #432 holding.
  • Moors & Cabot first reported a position in Axcelis in Q1 2021 and has held it in 22 quarters since.
  • Moors & Cabot's Axcelis position peaked at $1.88M in Q2 2023.
  • 441 funds tracked by Wall St. Rank held Axcelis as of Q2 2026.

Based on Moors & Cabot's 13F filing for Q2 2026, filed 10 Aug 2026.